Leukemia Posts Page 2 on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Can chronic myeloid leukemia patients discontinue dasatinib after a year of deep molecular response?

Posted by on May 12, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if dasatinib could be successfully discontinued in chronic myeloid leukemia patients who were receiving it as a second line treatment after a year of deep molecular response. This study concluded that it was possible to discontinue dasatinib use in this group of patients. Some background Imatinib...

Read More

Update on guidelines from the International Workshop on Chronic Lymphocytic Leukemia

Posted by on May 4, 2018 in Leukemia | 0 comments

In a nutshell This study reviewed updated guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Some background In 2008, the International Workshop on CLL (iwCLL) published guidelines for clinical trials for chronic lymphocytic leukemia (CLL) patients. These guidelines were...

Read More

Anti-thymocyte globulin to prevent complications after transplant in patients with acute lymphoblastic leukemia

Posted by on May 2, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effect of anti-thymocyte globulin on the outcomes of allogeneic peripheral blood stem cell transplantation in patients with Philadelphia negative acute lymphoblastic leukemia. This study concluded that this group of patients benefited from the use of anti-thymocyte globulin. Some background Stem cell...

Read More

Sorafenib to improve outcome after transplant for patients with FLT3-ITD acute myeloid leukemia

Posted by on May 1, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the effect of sorafenib (Nexavar) on the outcomes of patients with acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3)–internal tandem duplication (ITD) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study concluded that sorafenib before or after...

Read More

A new treatment combination for patients with relapsed/refractory chronic lymphocytic leukemia

Posted by on Apr 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of venetoclax (Venclexta) and rituximab (Rituxan) treatment in patients with relapsed/refractory chronic lymphocytic leukemia. This study concluded that venetoclax-rituximab treatment was effective for these patients.     Some background Chronic lymphocytic leukemia...

Read More

Switching from imatinib to dasatinib for chronic phase chronic myelogenous leukemia patients

Posted by on Apr 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if side effects of imatinib (Gleevec) treatment in chronic phase chronic myelogenous leukemia would improve if patients were switched to dasatinib (Sprycel) treatment. This study concluded that these patients experience improvements in side effects and quality of life once they switch treatment. Some...

Read More

Comparing conditioning regimens for adult patients with Ph-negative acute lymphoblastic leukemia treated with stem cell transplant

Posted by on Apr 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to compare two conditioning treatment regimens for adult patients with Ph-negative acute lymphoblastic leukemia treated with stem cell transplant. This study concluded that the regimen that combined etoposide (Etopophos) and total body irradiation was more effective than the regimen that combined cyclophosphamide (Neosar)...

Read More

How safe and effective is ponatinib for chronic phase chronic myeloid leukemia patients?

Posted by on Apr 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness and safety of ponatinib (Iclusig) for patients with chronic phase chronic myelogenous leukemia. This study concluded that ponatinib is safe and effective in this group of patients. Some background The Philadelphia chromosome (BCR-ABL1) is found in almost all patients with chronic...

Read More

Treatment options for chronic myeloid leukemia patients with failed imatinib treatment

Posted by on Apr 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of dasatinib (Sprycel) and nilotinib (Tasigna) in chronic phase chronic myeloid leukemia patients with failed imatinib (Gleevec) treatment. This study concluded that dasatinib and nilotinib were safe and effective in this group of patients. Some background Chronic...

Read More